Site Intelligence And Activation (SIA) Brochure

As drug development moves through a period of significant innovation and complexity, our industry is faced with extended development timelines, increased costs and the need for greater global harmonization and planning across development functions. These changes also have brought on increased regulatory challenges and cost pressures. Consequently, PPD’s study start-up process has rapidly evolved over the past five years to address these challenges and increase global coordination and consistency.

PPD has consolidated the vast majority of our start-up activities into one global business unit, Site Intelligence and Activation (SIA), under a single, global leader. PPD’s SIA group includes many service areas aligned in a uniquely holistic manner, including trial optimization/strategic feasibility, country/site selection, strategic site partnerships, investigator qualification, site activation (local regulatory submissions, site contracting and clinical start up) and patient recruitment.

We also have employed several state-of-the-art technologies to help us facilitate the process, with the end goal of PPD becoming the industry leader in site identification and activation. Benefits of this alignment include improved processes, industry-leading cycle times and additional flexibility in response to our clients’ outsourcing demands.